Rare HER2 L796P missense mutation promotes the growth and oncogenic signaling in breast cancer cells

Global challenges and policy solutions in breast cancer control

(2022) Dario Trapani et al.   CANCER TREATMENT REVIEWS

RAB5C, a new mRNA binding target of HuR, regulates breast cancer cell proliferation

(2022) Zhenzhen Wang et al.   CELL BIOLOGY INTERNATIONAL

HIPK2 in cancer biology and therapy: Recent findings and future perspectives

(2022) Andrea Conte et al.   CELLULAR SIGNALLING

Genomic alterations in PIK3CA-mutated breast cancer result in mTORC1 activation and limit sensitivity to PI3Kα inhibitors

(2021) Yanyan Cai et al.   CANCER RESEARCH

Precision medicine in breast cancer: from clinical trials to clinical practice

(2021) Edoardo Crimini et al.   CANCER TREATMENT REVIEWS

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

(2021) H.J. Burstein et al.   ANNALS OF ONCOLOGY

Anticancer drug resistance: An update and perspective

(2021) Ruth Nussinov et al.   DRUG RESISTANCE UPDATES

Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance

(2020) Andriy Marusyk et al.   CANCER CELL

The role of genomics in global cancer prevention

(2020) Ophira Ginsburg et al.   Nature Reviews Clinical Oncology

mTORC1 promotes TOP mRNA translation through site-specific phosphorylation of LARP1

(2020) Jian-Jun Jia et al.   NUCLEIC ACIDS RESEARCH

Breast cancer stem cells, heterogeneity, targeting therapies and therapeutic implications

(2020) Xiaobin Zeng et al.   PHARMACOLOGICAL RESEARCH

Prevalence and role of HER2 mutations in cancer

(2019) Emiliano Cocco et al.   PHARMACOLOGY & THERAPEUTICS

Consensus sequence design as a general strategy to create hyperstable, biologically active proteins

(2019) Matt Sternke et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HER2-targeted therapies — a role beyond breast cancer

(2019) Do-Youn Oh et al.   Nature Reviews Clinical Oncology

Dissecting the molecular recognition of dual lapatinib derivatives for EGFR/HER2

(2019) Martiniano Bello et al.   JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

(2019) Lillian M. Smyth et al.   Cancer Discovery

Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women

(2018) Ranjit Manchanda et al.   JNCI-Journal of the National Cancer Institute

Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women

(2018) Ranjit Manchanda et al.   JNCI-Journal of the National Cancer Institute

Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer

(2018) Sarah Croessmann et al.   CLINICAL CANCER RESEARCH

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

(2018) Emiliano Cocco et al.   Science Signaling

Mutation effects predicted from sequence co-variation

(2017) Thomas A Hopf et al.   NATURE BIOTECHNOLOGY

LARP1 functions as a molecular switch for mTORC1-mediated translation of an essential class of mRNAs

(2017) Sungki Hong et al.   eLife

Label-free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis

(2016) Jill A. Opsahl et al.   PROTEOMICS

Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

(2012) Ron Bose et al.   Cancer Discovery

A method and server for predicting damaging missense mutations

(2010) Ivan A Adzhubei et al.   NATURE METHODS

MutationTaster evaluates disease-causing potential of sequence alterations

(2010) Jana Marie Schwarz et al.   NATURE METHODS

EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation

(2008) T. Trowe et al.   CLINICAL CANCER RESEARCH